Analysis Of Income And Expense [Abstract]

Tchaikapharma High Quality Medicines AD - Filing #6023728

Concept 2023-01-01 to
2023-12-31
2023-01-01 to
2023-12-31
2023-01-01 to
2023-12-31
2023-01-01 to
2023-12-31
2023-01-01 to
2023-12-31
2023-01-01 to
2023-12-31
2023-01-01 to
2023-12-31
2022-01-01 to
2022-12-31
2022-01-01 to
2022-12-31
2022-01-01 to
2022-12-31
2022-01-01 to
2022-12-31
2022-01-01 to
2022-12-31
2022-01-01 to
2022-12-31
2022-01-01 to
2022-12-31
Analysis of income and expense [abstract]
Revenue [abstract]
Revenue
48 512 BGN
43 146 BGN
Expenses by nature [abstract]
Raw materials and consumables used
12 172 BGN
13 954 BGN
Cost of merchandise sold
862,000 BGN
752,000 BGN
Services expense
20 271 BGN
17 964 BGN
Classes of employee benefits expense [abstract]
Employee benefits expense
7 333 BGN
6 023 BGN
Depreciation, amortisation and impairment loss (reversal of impairment loss) recognised in profit or loss [abstract]
Depreciation and amortisation expense [abstract]
Depreciation and amortisation expense
2 809 BGN
3 568 BGN
Other expenses, by nature
899,000 BGN
456,000 BGN
Disclosure of attribution of expenses by nature to their function [text block]
Disclosure of attribution of expenses by nature to their function [abstract]
Disclosure of attribution of expenses by nature to their function [line items]
Comprehensive income, continuing and discontinued operations [abstract]
Comprehensive income
- BGN
- BGN
3 416 BGN
18,000 BGN
- BGN
3 398 BGN
3 416 BGN
- BGN
24,000 BGN
- BGN
2 766 BGN
2 766 BGN
2 790 BGN
- BGN
Comprehensive income attributable to owners of parent, continuing and discontinued operations [abstract]
Comprehensive income, attributable to owners of parent
3 416 BGN
2 766 BGN
Comprehensive income attributable to non-controlling interests, continuing and discontinued operations [abstract]
Comprehensive income, attributable to non-controlling interests
- BGN
- BGN

Talk to a Data Expert

Have a question? We'll get back to you promptly.